Hyloris Pharmaceuticals SA is a Belgium-based bio-pharmaceutical company. The Company focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. It has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. It also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.

• Revenue in EUR (TTM)2.81m
• Net income in EUR-15.76m
• Incorporated2017
• Employees24.00

• Location
  Hyloris Pharmaceuticals SABoulevard Gustave Kleyer 17LIEGE 4000BelgiumBEL
• Phone+32 43460207
• Websitehttps://hyloris.com/